HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, will host a conference call on August 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call, led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, will include a question-and-answer session following prepared remarks.
The announcement underscores HeartBeam's commitment to transforming cardiac monitoring through its innovative 3D ECG technology. The company is creating the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care outside medical facilities, redefining cardiac health management.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. These milestones are critical as the company seeks to expand its market presence and drive adoption of its platform globally.
The upcoming call will provide investors and stakeholders with insights into the company's financial performance and strategic direction. With a focus on accelerating global adoption, HeartBeam aims to leverage its FDA-cleared technology to meet the growing demand for remote cardiac monitoring solutions. The company's ability to deliver a cable-free, portable ECG system positions it uniquely in the medtech landscape, potentially offering significant advantages over traditional ECG devices.
Investors can access the full press release for more details at https://ibn.fm/sqGLs. For the latest news and updates on HeartBeam, visit the company's newsroom at https://ibn.fm/BEAT. Additional information on cleared indications for use is available at https://www.heartbeam.com/indications.
